An interventional study of Smartphone app-based Intervention (Actify! A app) and Smartphone app-based Intervention (Actify! B app) in Cigarette Smoking-Related Carcinoma, sponsored by Fred Hutchinson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Fred Hutchinson Cancer Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 371 studies in Cigarette Smoking with a site in United States — 68 open to participants now, 75 under way, 3 of them phase 3. Cigarette Smoking · United States.
Among the 371 studies in Cigarette Smoking with a site in United States, this one is the 14th largest by planned enrollment of the 340 interventional ones that give a count, is one of 7 that started in 2027, is one of 226 with no phase, reaches primary completion later than 62 of the 74 other live ones, and was the 357th registered.
477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.
Browse Cigarette Smoking studies →68 of the 371 studies in Cigarette Smoking with a site in United States are open now. Recruiting first, the newest first:
Roswell Park Cancer Institute · Sites in United States
Ages 18–30
Virginia Polytechnic Institute and State University · Sites in United States
Ages 21+
University of California, Irvine · Sites in United States
Ages 50–80
VA Office of Research and Development · Sites in United States
Ages 21+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 21–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
371 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 56 · Phase 3 10 · Phase 4 22
First in 1997; this study’s year is marked. 7 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,812 is above the median of 96 across 407 interventional studies indexed under Cigarette Smoking.
Median enrollment 96 across the 340 interventional studies, 159 across the 30 observational. Of the 280 that completed or were terminated, 137 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 371 have an industry lead sponsor. The 10 most frequent:
Fred Hutchinson Cancer Center is the lead sponsor of 547 studies on the registry; 79 are open to participants now.
Of its 59 completed or terminated interventional studies of FDA-regulated products, 46 (78%) have results posted.
Fred Hutchinson Cancer Center has 9 studies filed under Cigarette Smoking — fewer than ten, so there is no comparison to draw.
34 of the studies in Cigarette Smoking with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT05008848Phase 3Alliance for Clinical Trials in OncologyReaching Rural Cancer Survivors Who Smoke Using Text-Based Program | 2027-04-23 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT05836103Johns Hopkins Bloomberg School of Public HealthTesting the Impact of Smartphone-based Messaging to Support Young Adult Smoking Cessation | 2026-11-30 |
| NCT05707871Wake Forest University Health SciencesCardiovascular Effects of Very Low Nicotine Content Cigarettes | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 371 studies in Cigarette Smoking with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial compares two smartphone applications, called Actify! (A \& B) for improving smoking cessation outcomes in individuals who smoke. Actify! A is an app grounded in behavioral activation therapy, an evidence-based treatment for depression that can also be used to modify health behaviors such as smoking. The Actify! B app provides evidence-based tobacco cessation strategies based on current clinical guidelines.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I: Participants use the Actify! A app, which helps users identify personal values and meaningful activities, prompts users to schedule and complete meaningful activities, visualizes progress towards meeting activity and smoking-related goals, and provides tailored messages, resources, daily tips, personalized feedback, inspirational messages, and user stories, for 8 weeks on study.
ARM II: Participants use the Actify! B app, which contains quit advice, tools for tracking smokefree days, progress and cravings, guidance on preparing to quit, managing cravings and withdrawal, recovering from slips, and a mood management feature, for 8 weeks on study.
After completion of study intervention, participants are followed up at 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants use the Actify! app, which helps users identify personal values and meaningful activities, prompts users to schedule and complete meaningful activities, visualizes progress towards meeting activity and smoking-related goals, and provides tailored messages, resources, daily tips, personalized feedback, inspirational messages, and user stories, for 8 weeks on study.
Behavioral: Smartphone app-based Intervention (Actify! A app) · Other: Health Promotion and Education · Other: Survey Administration
Participants use an app, which contains quit advice, tools for tracking smokefree days, progress and cravings, guidance on preparing to quit, managing cravings and withdrawal, recovering from slips, and a mood management feature, for 8 weeks on study.
Behavioral: Smartphone app-based Intervention (Actify! B app) · Other: Health Promotion and Education · Other: Survey Administration
Use Actify! A app
Use Actify! B app
Receive motivational messages and smoking cessation information via text messages
Ancillary studies
Self-reported 30-day point prevalence abstinence (PPA) from cigarette smoking
Percentage of participants self-reporting no smoking over the previous 30 days
Time frame: At 6 months post-randomization
Biochemically-confirmed 30-day PPA from cigarette smoking
Percentage of participants reporting no smoking over the previous 30 days, confirmed via carbon monoxide testing
Time frame: At 6 months post-randomization
Self-reported 7-day PPA from cigarette smoking
Percentage of participants reporting no cigarette smoking over the prior 7 days
Time frame: At 8 weeks post-randomization
Self-reported 7-day PPA from cigarette smoking
Percentage of participants reporting no cigarette smoking over the prior 7 days
Time frame: At 6 months post-randomization
Self-reported 7-day PPA from use of all nicotine/tobacco products except Food and Drug Administration (FDA)-approved medications
Percentage of participants reporting no smoking over the prior 7 days and no use of any other nicotine/tobacco product except FDA-approved medications (e.g, nicotine patch or gum)
Time frame: At 8 weeks post-randomization
Self-reported 7-day PPA from use of all nicotine/tobacco products except FDA-approved medications
Percentage of participants reporting no smoking over the prior 7 days and no use of any other nicotine/tobacco product except FDA-approved medications (e.g, nicotine patch or gum)
Time frame: At 6 months post-randomization
Self-reported 30-day PPA from use of all nicotine/tobacco products except FDA-approved medications
Percentage of participants reporting no smoking over the prior 30 days and no use of any other nicotine/tobacco product except FDA-approved medications (e.g, nicotine patch or gum)
Time frame: At 8 weeks post-randomization
Self-reported 30-day PPA from use of all nicotine/tobacco products except FDA-approved medications
Percentage of participants reporting no smoking over the prior 30 days and no use of any other nicotine/tobacco product except FDA-approved medications (e.g, nicotine patch or gum)
Time frame: At 6 months post-randomization
Biochemically confirmed 7-day PPA from use of all nicotine/tobacco products except FDA-approved medications
Percentage of participants reporting no smoking over the prior 7 days and no use of any other nicotine/tobacco product except FDA-approved medications (e.g, nicotine patch or gum), confirmed via carbon monoxide and cotinine testing
Time frame: At 6 months post-randomization
Biochemically confirmed 30-day PPA from use of all nicotine/tobacco products except FDA-approved medications
Percentage of participants reporting no smoking over the prior 30 days and no use of any other nicotine/tobacco product except FDA-approved medications (e.g, nicotine patch or gum), confirmed via carbon monoxide and cotinine testing
Time frame: At 6 months post-randomization
Plan to share: Yes — The study researchers for this study plan to preserve and share the following: Survey Data: De-identified individual and aggregate survey data (including raw and recoded data) necessary to replicate main outcomes will be shared. The de-identification process will remove direct and indirect respondent identifiers prior to sharing. App utilization data: Individual level, de-identified aggregate data necessary to replicate main outcomes (e.g., summary number of log-ins, pages viewed, or other app events) will be shared. The de-identification process will remove direct and indirect respondent identifiers. Documentation made publicly available to the research community will include PDFs of various study materials. At this time, the study researchers plan to share scientific data and meta-data in NCI's Cancer Data Service (CDS): https://dataservice.datacommons.cancer.gov/#/home.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Final data submission and release of data used in publications will occur at the time of publication. Other shared data will be made available at or before the end of the project period. The study researchers will follow the data retention plan of the final selected repository, but at a minimum, researchers intend to ensure that data is available for a period of not less than 5 years after the end of this trial.
Access criteria: All data sharing will be done in compliance with NIH data sharing policies, applicable laws and regulations, and in accordance with guidance from journal publishers. CDS allows open and controlled access to data to ensure access is provided to qualified researchers, data access is tracked, and users understand how to cite and credit use of the data. Data will only be shared for non-profit, non-commercial and non-proprietary purposes to qualified researchers or as allowed by CDS. Based on the nature of the data, which is not sensitive, the study researchers anticipate making it publicly available (as opposed to controlled access) but will follow final recommendations from the IRB as to whether access should be controlled.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jul 2029, 30 months later.
Of 185 non-industry interventional studies with no phase under Cigarette Smoking, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 30 months is above that.
Counting every sponsor, half of 192 studies reached it within 20 months; a quarter within 8 and three quarters within 32.
Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Jan 2027, on Nov 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fred Hutchinson Cancer Center →